Avicanna (OTCPK:AVCN.F) Update / Briefing Transcript

Avicanna Inc. Update Summary Company Overview - Company: Avicanna Inc. (OTCPK: AVCN.F) - Founded: 2016, initially focused on pharmaceutical drug development - Current Focus: Medical cannabis commercialization and pharmaceutical pipeline development [2][3] Business Pillars 1. Rofido: Medical finished products in Canada and international markets [3] 2. MyMedi: A complete medical cannabis care platform providing patient support and access [3][20] 3. Pharmaceutical Pipeline: Ongoing development of pharmaceutical products, with the first drug approval achieved [3][19] 4. Aureus: API and raw material division based in Colombia, supplying cannabinoid APIs to international companies [4][16] Key Developments - Product Expansion: Increased commercial SKUs from 42 to 52, a 24% increase [8] - New Medical Channels: Expanded into three new medical channels, including partnerships with competitors [9] - RHO Phyto Portfolio: Flagship product line with 30 SKUs, focusing on cannabinoid-based treatments [10][11] - R&D Advancements: Conducted over 30 R&D trials, with new product lines including deep tissue gel and nano gummies [5][12][13] Financial Performance - Revenue Growth: Modest year-over-year revenue growth, with improved margins due to service and licensing projects [32][33] - Cost Management: Reduction in SG&A expenses through efficiency efforts [34] - Cash Position: Relatively weak balance sheet but improved working capital [35][36] Market Opportunities - International Expansion: Initial exports of cannabinoid flower to Switzerland and plans for further European and Australian markets [16][17] - Trunerox Launch: First pharmaceutical-approved product for epilepsy, with significant market potential [19][51] - MyMedi's Role: Positioned as a leading platform for medical cannabis, aiming to legitimize and expand access [38][56] Strategic Initiatives - Intellectual Property Focus: Continued expansion of patent portfolio, including a new patent for a dermatology topical [29][30] - Partnerships: Collaborations with Fortune 100 and 500 companies to enhance scale and market reach [44] - U.S. Market Entry: Preparedness for potential U.S. market entry, leveraging existing platforms and products [45][61] Challenges and Considerations - Market Sentiment: Current positioning as a cannabis company limits value creation despite strong fundamentals [37] - Regulatory Landscape: Navigating the complexities of medical cannabis regulations in various markets [54][55] Future Outlook - 2026 Expectations: Anticipated scale-up of operations, further product development, and potential entry into the U.S. market [46][62] - Continued R&D Investment: Focus on advancing clinical trials and expanding the pharmaceutical pipeline [42][43] Conclusion Avicanna Inc. is positioned for growth with a strong focus on medical cannabis and pharmaceutical development, backed by a solid R&D foundation and strategic partnerships. The company aims to leverage its unique platform, MyMedi, to expand its market presence and enhance patient access to cannabinoid-based treatments.